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The research on metabolically stable compounds makes it possible not only to clarify 
various life phenomena, but also to utilize more stable compounds which are useful for 
various research of life sciences. In this thesis, I investigated metabolically stable 
compounds through kinetics and biochemical analysis.  
In chapter 1, I investigated metabolic process of S-nitrosocysteine, which is one of 
endogenous S-nitrosothiols well known as an NO donor. Kinetics study revealed that 
S-nitrosocysteine had much longer half-life than NO in the presence of cysteine, which 
mimics a physiological condition. This result indicated that low-molecular-weight 
S-nitrosothiols, such as S-nitrosocysteine, could play a role as a sustainable NO donor in 
vivo, implying that S-nitrosothiols were the most suitable NO-generating agents for 
useful research tools but also possessed a potential for treatment of cardiovascular 
diseases. In chapter 2, I characterized the difference between M1 and M2-polarized 
macrophages using two types of metabolically stable chemical probes, 
2-fluoro-2-deoxy-D-glucose (FDG) and ultrasmall superparamagnetic iron oxide (USPIO) 
particles. FDG and USPIO were useful clinical imaging agents for atherosclerosis. The 
analyses of intracellular accumulation of these chemical probes in human THP-1-derived 
macrophages indicated that M1-polarized inflammatory macrophages preferentially 
accumulated FDG than USPIO, due to upregulation of both glucose uptake and 
phosphorylation in M1 macrophages. This result suggested that FDG can be more useful 
than USPIO as an imaging probe that detects the M1-polarized inflammatory 
macrophages, which promote destabilization of plaques. 
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In summary, metabolically stable compounds are effectively useful as tools for not 
only investigating life phenomena, but also making diagnosis with a profound biological 
understanding of disease. 
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CCR7  CC chemokine receptor7 
CD  cluster of differentiation 
Cys-SH  cysteine 
Cys-SNO S-nitrosocysteine 
FDG  2-fluoro-2-deoxy-D-glucose 
FPN1  ferroportin 1 
FTL  ferritin light chain 
GLUT  glucose transporter 
G6P  glucose-6-phosphate 
G6Pase  glucose-6-phosphatase 
hIFN  human interferon- 
hIL  human interleukin 
HK  hexokinase 
iNOS  inducible nitric oxide synthase 
LPS  lipopolysaccharide 
MRC1  mannose receptor, C type 1 
MRI  magnetic resonance imaging 
NO  nitric oxide 
PET  positron emission tomography 
PMA  phorbol 12-myristate 13-acetate 
SR-A  scavenger receptor A 
USPIO  ultrasmall superparamagnetic iron oxide particles 
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In all living organisms, including human, complex biochemical reactions are strictly 
regulated for sustainability of a life. Metabolism is one of the most important body 
regulation systems and comprises of several biochemical reactions (Newsholme EA, 1973; 
Martin BR et al., 1987). There are mainly three types of essential metabolic reactions, 
anabolism, catabolism and detoxification. Anabolism is a construction process of large 
molecules from smaller units, while catabolism is a break down process from large 
molecules into smaller subunits to generate energy. Similar to catabolism, another type of 
break down process in a higher organism is digestion which promotes absorption and 
assimilation of substances into a body (McGilvery, RW et al., 1983; Abeles RH et al., 1992). 
In general, a living organism takes substances from outside, and metabolizes it to 
generate energy in the form of ATP or to produce parts of cellular components. The 
metabolites were produced by the degradation process of large molecules – carbohydrate, 
protein and fat – taken as a nutrient, and convert into different form of cellular/body 
components. The components was used as a structure of a body, or preserved as an energy, 
and utilized it for life activities. Substance and energy exchanges ceaselessly between 
outside and inside of a body. This process is essential not only for maintenance of a body 
but also for power generation. Detoxification is an inactivation reaction of toxic 
substances derived from both endogenous and exogenous origins (Wanders RJ, 2013). 
Moreover, many other biochemical reactions related to metabolic pathway, such as signal 
transduction, contribute to the sustainability of living creatures. Various biochemical 
reactions associated with a metabolism continues as long as they are alive, reacting 
constantly against external environment changes. In this way, the living organisms have 
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an essential system called “homeostasis”, which maintains static condition of a body as a 
macro level by the active biochemical reactions as a micro level, in other words, dynamic 
equilibrium. 
Dynamic equilibrium is a balance and flow of building block of a body; not only an 
exchange of cellular components but also food intake contribute to the homeostasis 
(Schoenheimer R, 1946). Glucose metabolism is a typical example of physiological 
regulation of metabolic status. Food-derived carbohydrates, such as sucrose and starches, 
are enzymatically digested to origo- and mono-saccharide, including glucose, and then 
absorbed into a small intestine and dispersed throughout a body via blood stream. 
Glucose is used to generate energy, as a form of ATP, by both glycolysis and tricarboxylic 
acid (TCA) cycle in several tissues. Moreover, excess mount of glucose is stored as 
glycogen in liver or as lipids in fat. Glucose is so important, as an energy source of every 
organ. Several feedback systems strictly regulate plasma glucose level. Significantly low 
plasma glucose level called hypoglycemia causes disruption of brain function due to a lack 
of energy supply, resulting in severe symptoms such as seizure, consciousness 
disturbance and lethargy. On the other hand, chronic high blood glucose level called 
hyperglycemia damages several tissues due to an accumulation of protein modifications 
by glucose itself. Insulin is a hormone produced by β-cells in the pancreas, regulating the 
metabolism of carbohydrates by sensing plasma glucose level. Insulin activates 
absorption of glucose into skeletal muscles and fat tissue, and accelerated intracellular 
glucose metabolisms such as glycolysis and lipid biosynthesis as well. Similar to 
carbohydrate, food-derived protein is also digested to amino acids in an intestine, and 
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then absorbed into a body. The absorbed amino acids are transferred to liver through 
blood capillary and portal vein. A part of these amino acids is reused for protein 
biosynthesis; especially food-derived essential amino acids are important sources of 
proteins synthesis in a body. The other portion of amino acids is metabolized. The first 
step of the amino acid metabolism is a removal of amino group, which is becomes 
ammonium ion, and then incorporated into Urea cycle, and finally excreted from a kidney 
as a form of urea. After removal of amino group, the carbon skeleton is further 
metabolized to organic acids, some of which are introduced into energy generation cycle, 
such as TCA cycle, or are used for biosynthesis of glucose (gluconeogenesis) and ketone 
body as the other form of energy. Cellular amino acid level is maintained at a same level 
by mixing with food-derived amino acids and body protein derived amino acids, which is 
called Amino acid pool. Imbalance of amino acid pool sometimes cause imbalance of a 
body function because amino acid plays multiple roles by transforming to both energy 
sources and building block of a cell, such as protein and lipid. Lipid derived from food 
components and de novo biosynthesis process distributed in different forms, such as 
phospholipid and acylglycerol. Phospholipid is main component of cellular/subcellular 
membrane. Acylglycerol, especially triacylglyerol, is stored in adipose tissues as a form of 
energy storage. When supply of glucose is restricted like starvation condition, amino acid 
and lipid become alternative sources of energy. Free fatty acids hydrolyzed from 
triacylglycerol distribute to several parts of body via blood flow. In cells, the free fatty acid 
is incorporated into mitochondria, and decomposed by β-oxidation pathway to generate 
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energy. The dynamic metabolism of carbohydrate, protein and lipid contribute to the 
main part of homeostasis, determining physical condition of a body.  
Meanwhile, local and transient reactions, such as acute protective response and 
signal transduction, are also indispensable systems of life. Nitric oxide (NO) is a signaling 
molecule, synthesized by an enzyme called NO synthase. NO transmits various biological 
signals in variety of cells and tissues, such as regulation of blood flow, neurotransmission, 
and mediation of immunological responses (Bredt DS, 1994). NO functions locally and 
promptly since NO is immediately disappears due to the instability. Body protection 
system is another example of acute reaction. For example, acute inflammatory response 
locally occurs immediately after an infection of virus or microorganisms, and gradually 
goes into a suppressive immunization process with the decline of the external stimuli 
(Levy JH, 1996). Inflammatory response is one of the most complex biological processes 
by various biochemical substances in different types of cells. This system is too 
complicated to figure out the whole picture yet. 
Various chemical reactions constantly happen in vivo. Clarifying a mechanism of 
biochemical reactions and its complicate combination in a body is a critical issue of 
biochemistry and biology research. Chemical kinetics becomes a strong tool to elucidate a 
mechanism of biological reactions in molecular level. A major player in biological reaction 
is enzyme, whose diversity is significant and contribute to almost all chemical alteration 
in a body. Therefore, enzymatic kinetics research could reveal not only the enzymatic 
machinery the activity regulation, but also boost a biology research and a drug 
development. Theoretically, uncovering reaction-rate-equation of every enzyme in a 
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biological system could reveal all rate-constants that decide speeds of every reaction, 
which could unveil entire biological system (Cook PF et al., 2007). A precise 
understanding of respective reactions requires a simplified system focusing on each 
biological reaction, although sophisticated biological systems is established with an 
elaborated of individual reactions; large number of intermediates and the sub-reactions 
and reverse reactions makes the physiology complicated. 
Enzymatic reaction experiments are performed by using a recombinant enzyme; 
concentration monitoring of substrates and products can reveal the kinetics of the 
enzyme. This is a most simplified experiment for enzymatic reaction, but often difficult to 
estimate actual function in a complex biological system because of the complex 
molecular/cellular/tissue interactions. Popular approach to investigate the real function 
of an enzyme in a body is a tracer experiment. For example, after adding isotope-labeled 
glucose, such as 13C-labeled or 14C-labeled, in cells/tissues, monitoring concentration 
change of isotope-labeled glucose and generation of isotope-labeled glucose metabolites 
could clarify the fate and kinetics of glucose metabolism in a biological system. In this 
type of study, nucleic magnetic resonance spectroscopy (NMR) and mass spectrometry 
(MS) play a powerful role to monitor labeled molecules. As for in vivo molecular kinetics 
research, molecular imaging modalities – positron emission tomography (PET), 
single-photon emission computed tomography (SPECT), functional magnetic resonance 
imaging (fMRI) – are able to monitor dynamic flow of labeled- or endogenous molecules 
(Osborn EA et al., 2013). [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET is often used for 
detection of tumor because of the active glucose uptake (flow) in cancer cells (Smith TA, 
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1998), and for studying glucose utilization (kinetics) in several tissues as well. Hence, 
imaging technologies and high sensitive molecular probes that visualize the specific 
molecular pathway in a body have become valuable tools for several life science fields. 
In this thesis, I investigated the usefulness of metabolically stable compounds, such 
as S-nitrosocysteine, FDG, and USPIO, as tools for various biological approaches. In 
Chapter 1, the decomposition kinetics of S-nitrosocysteine, one of endogenous 
S-nitrosothiols, were investigated in order to understand its usefulness as a sustainable 
NO donor. I discussed the physiological role and usefulness of S-nitrosocysteine and the 
future perspective to its clinical translation, led by my study. In Chapter 2, 
M1/M2-polarized macrophages were characterized using two types of chemical probes, 
FDG and USPIO, which were metabolized through different pathways. Biological readout 
of the imaging using FDG and USPIO in atherosclerosis was discussed based on kinetic 
research of these compounds in the different type of macrophages. I also discussed the 
results from the point of view of translational research. 
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Chapter 1 
 
Kinetic Studies on the Reaction of S-nitroso-L-cysteine  
with L-cysteine 
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Abstract 
 
Kinetics for the reaction of S-nitroso-L-cysteine (S-nitrosocysteine) decomposition in 
the presence of L-cysteine (cysteine) were examined in a physiological condition, with an 
aim to find out if S-nitrosothiols have stability to reserve and transport nitric oxide (NO) 
in a body. Rates for the reaction between S-nitrosocysteine and cysteine were found to be 
first order with respect to concentrations of the two reactants in the pH range of 4.85 - 
9.41. The second order rate constant was determined to be 3.10 x 10-2 M-1s-1 at pH7.4 at 
37°C. Spontaneous decomposition of S-nitrosocysteine proceeded with the first order rate 
constant, 1.46 x 10-5 s-1 under the same conditions. These rate constants for the 
decomposition of S-nitrosocysteine as one of endogenous S-nitrosothiols in the presence of 
cysteine at pH7.4 at 37°C leaded to estimate the half-life of S-nitrosocysteine in a 
physiological condition. The half-life of S-nitrosocysteine was calculated to be 75 min 
based on the k2 value in the presence of cysteine under this experimental condition, and 
was much longer than NO. This kinetic result suggests that S-nitrosocysteine stability is 
sufficient to function as a reservoir and transporter of NO in physiological environments, 
such as blood and cytosol. 
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Introduction 
 
Nitric oxide (NO) is a biological messenger molecule produced in mammals via the 
oxidation of L-arginine to citrulline by NO synthase, which NO is observed in a wide 
variety of cell types, including macrophages, vascular endothelial cells, neurons, 
epithelial cells, and neutrophils (Marletta MA, 1993). For example, soluble guanylate 
cyclase contains heme as a prosthetic group, and is activated up to 200-fold increase in 
catalytic rate, i.e. the conversion of GTP to cyclic guanosine monophosphate (cGMP) by 
the binding of NO to that heme (Derbyshire ER et al., 2009). In blood vessels, cGMP as a 
second messenger induces relaxation of vascular smooth muscles and inhibition of 
platelet aggregation leading to vasodilation and increased blood flow. NO was identified 
as endothelium-derived relaxing factor (EDRF) (Ignarro LJ, 1989; Ignarro LJ et al., 1987; 
Palmer RMJ et al., 1987; Furchgott RF, 1988; Feelisch M et al., 1994), but S-nitrosothiols 
had also been considered to be one of most plausible candidates for EDRF in times past 
(Ignarro LJ, 1989). Meanwhile, the accumulated observations, as indicated by the 
following examples, suggest that NO is reserved and transported as nitrosothiols, the 
carriers, which then give their NO to metal prosthetic groups or cysteine residues of the 
target proteins to transduce signaling: (a) NO reacts readily with thiols to give the 
corresponding S-nitrosothiols (reaction 1) (Stamler JS et al., 1992p1; Stamler JS et al., 
1992s; Stamler JS et al., 1992p2; Girard P et al., 1993; Rand MJ et al., 1995). (b) 
S-nitrosothiols are much more stable than NO, which is a labile free radical with the 
biological half-life of several seconds. Cys-34 residue of serum albumin is nitrosylated to 
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form long-lived S-nitrosoalbumin which may act as a reservoir and carrier of NO in 
plasma (Simon DI et al., 1993; Shcarftein JS et al., 1994). (c) Thiols potentiate the action 
of NO. For example, relaxant action of NO on the rat anococcygeus muscle is much 
greater and more prolonged in the presence of cysteine (Cys-SH) than in its absence 
(Rand MJ et al., 1995). S-nitrosocysteine (Cys-SNO) is a more potent relaxant of 
endothelium-denuded strips of rabbit aorta than NO. S-nitrosothiols provide NO to 
soluble guanylate cyclase (Feelisch M et al., 1994). The NO binding to the heme moiety of 
the guanylate cyclase triggers the generation of cyclic GMP, the next messenger in the 
NO-mediated signaling pathway. (d) Nitroso group transfer, transnitrosation (reaction 3) 
between S-nitrosothiols and thiols takes place readily (Shcarftein JS et al., 1994; Arnelle 
DR et al., 1995; Barnett DJ et al., 1994; Barnett DJ et al., 1995). (e) S-nitrosation of 
cysteine residues of the particular proteins modulates their functions (Jia L et al., 1996; 
Hajjar DP et al., 1995; Gross WL et al., 1996; Mohr S et al., 1994; Stamler JS, 1994). 
 
 R-SH + NO → R-SNO + H+ + e- (1) 
 R-SNO → 1/2 R-S-S-R + NO  (2) 
 R-SNO + R'-SH → R-SH + R'-SNO (3) 
 R-SNO + R'-SH → R-S-S-R' + HNO (4) 
 
Since all physiological events are rate processes, understanding the biological roles of 
S-nitrosothiols requires rates and mechanisms of the key reactions 1-4 in regard to 
S-nitrosothiols. The kinetics data and mechanisms for the Cys-SNO-forming reaction of 
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NO with cysteine (reaction 1) were previously reported by two groups (Kharitonov VG et 
al., 1995; Goldstein S et al., 1996). When the reaction 1 is carried out under aerobic 
conditions, oxygen molecule acts as the electron acceptor (Kharitonov VG et al., 1995; 
Goldstein S et al., 1996). Kinetic studies on the transition metal ion-catalyzed 
NO-regenerating process from S-nitrosothiols (reaction 2) were investigated by Williams 
et al. (McAninly JJ et al., 1993; Askew SC et al., 1995). Arnelle and Stamler showed in 
their in vitro semi-quantitative studies of the reaction 2 that the apparent life times of 
S-nitrosothiols vary depending on the analytical methods (Arnelle DR et al., 1995). The 
kinetics and mechanisms of the transnitrosation from S-nitrosothiols to thiols (reaction 3) 
were extensively studied by Williams and coworkers (Barnett DJ et al., 1994; Barnett DJ 
et al., 1995). 
In this way, although thiols produce S-nitrosothiols in biological systems, they also 
destroy S-nitrosothiols to give disulfides (reaction 4) as reported by Oae et al (Oae S et al., 
1977). On the contrary, Feelisch et al. reported that the life-time of Cys-NO is prolonged 
by the presence of cysteine in a concentration-dependent manner (Feelisch M et al., 1994). 
Since the thiol concentration level in normal living cells is pretty high (ca. 5 mM) (Schultz 
et al., 1979), the decomposition reaction of S-nitrosothiols with thiols (reaction 4) is of 
importance but its kinetics study has not as yet been reported. Thus, I conducted the 
kinetic studies of the decomposition reaction of Cys-SNO in the presence and absence of 
Cys-SH to solve these problems. 
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Materials and Methods 
 
Preparation of Cys-SNO 
L-cysteine (cysteine, Cys-SH) was allowed to react with an equimolar amount of 
nitrous acid in an aqueous solution of pH 1-2 for 3 min at room temperature. The pH of 
the solution was raised to 7 by adding a NaOH solution quickly. The solution of 
S-nitroso-L-cysteine (S-nitrosocysteine, Cys-SNO) was treated with Chelex 100 ion 
exchange resin (Bio-Rad) on ice to remove any trace heavy metal ions which might be 
contained in the solution. Buffer solutions and Cys-SH solution were also treated with 
Chelex 100 ion exchange resin, since heavy metal ions, especially Cu+, catalyze the 
decomposition of nitrosothiols as noted by Williams et al (McAninly JJ et al., 1993; Askew 
SC et al., 1995). All the solutions contained 0.1 mM ethylendiaminetetraacetate (EDTA) 
to protect Cys-SNO from the heavy metal catalyzed decomposition. The solution of 
Cys-SNO thus prepared is stable for a few days on ice and is stored protected from light. 
 
 Cys-SH + HONO → Cys-SNO + H2O (5) 
 
Molar Extinction Coefficient of Cys-SNO 
Equimolar amounts of known concentration of Cys-SH in 0.1 M HCl solution and 
aqueous sodium nitrite (NaNO2) solution were mixed in a quartz UV cuvette and the 
increasing absorbance at 543 nm was recorded. After 3 min the absorbance reached to 
plateau. The value of e was calculated from the maximum absorbance of 852 M-1cm-1 
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(max 335 nm) and 16.8 M-1cm-1 (max 543 nm) by assuming that Cys-SH was converted 
to Cys-SNO quantitatively. The experiment was repeated 3 times and was reproducible. 
The same value was obtained under argon atmosphere. 
 
Absorbance Determination of Cys-SNO 
UV-visible spectra of Cys-SNO were recorded on a JASCO Ubest-50 
spectrophotometer equipped with a quartz UV cuvette with a water jacket to which water 
of 37 ± 0.1°C was circulated from a NESLAB RTE-210 refrigerated bath. When a 
microsyringe with a stainless steel needle and piston to transfer Cys-SNO into a UV 
cuvette was used, metal ion catalyzed decomposition of Cys-SNO took place rapidly at an 
unreproducible rate. Therefore, these solutions were pipetted by an eppendorf-pipette. All 
the pH values were measured at 37°C by Horiba M-13 pH meter. The following buffer 
solutions were used: pH5-6, sodium acetate; pH6-8, sodium phosphate; pH8-9, sodium 
borate. 
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Results 
 
Since most of thiols contained in peptides and proteins come from cysteine residues, 
kinetics of the reaction of Cys-SNO with Cys-SH (reaction 6) were studied. Both the 
nucleophilic substitutions on the nitroso-nitrogen (reaction 3) and on the sulfer (reaction 
4) of an S-nitrosothiol with a thiol are orbital controlled reactions (Oae S et al., 1978; 
Klopman G et al., 1974) and therefore these reactions may occur smoothly. The reversible 
transnitrosation reaction 3 and the irreversible reaction 4 take place competitively 
(Arnelle DR et al., 1995). However, since R and R' are the same in this work, the reaction 
3 does not interfere in the kinetic investigation of the reaction 6. Three fates await the 
HNO formed by the reaction 6, i.e. the condensation reaction 7 to give dinitrogen oxide, 
single electron oxidation affording NO (reaction 8) (Fukuto JM et al., 1993), and the 
reduction by thiol affording hydroxylamine (reaction 9) (Arnelle DR et al., 1995). In 
accordance with the observation by Arnelle and Stamler (Arnelle DR et al., 1995), no 
hydroxylamine was detected in the reaction mixture of Cys-SNO with Cys-SH, suggesting 
that HNO disappears via the reactions 7 and 8. 
 
 Cys-SNO + Cys-SH → Cys-S-S-Cys + H+ + NO- (6) 
 2 NO- + 2H+ → N2O + H2O (pKa of HNO = 4.7)
  (7) 
 NO- + ox → NO +  ox-     (8) 
 NO- + 2Cys-SH + H+ → H2NOH + Cys-S-S-Cys  (9) 
 Cys-SNO → Cys-S-S-Cys + NO    (10) 
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The kinetic measurements of the reaction between Cys-SNO and Cys-SH were 
carried out by adding the Cys-SH solution to the Cys-SNO solution in the UV cuvette at 
37.0°C and recording the absorbance of Cys-SNO at 335 nm or 543 nm. The rates were 
calculated from the slope of the time courses of the absorbance at the initial stage. When 
[Cys-SNO] was fixed to a value of 9.5 mM, the initial decay rates of Cys-SNO increased 
linearly with [Cys-SH] as shown in Fig. 1 (A). In the absence of Cys-SH the very slow 
unimolecular spontaneous decomposition of Cys-SNO proceeded with the first order rate 
constant (1.46 ± 0.08) x 10-5 s-1. With a fixed [Cys-SH] of 24.5 mM, the initial rates of 
Cys-SNO decay correlated linearly with [Cys-SNO] as shown in Fig. 1 (B). From these 
observations, one obtains the rate equation 11. 
 
 V = k1[Cys-SNO] + k2[Cys-SNO][Cys-SH]  (11) 
 
The second order rate constants (k2) were calculated from the slope of the line in Fig. 
1 (A) to obtain (2.20 ± 0.07) x 10-2 M-1s-1. From eqn. 11, the slope of the line in Fig. 1 (B), 
(2.20 ± 0.03) x 10-2 M-1s-1, is equal to (k2 + k1/[Cys-SH]). Substituting k1 and [Cys-SH] with 
1.46 x 10-5 s-1 and 24.5 mM in this equation, one gets k2 = 2.14 x 10-5 s-1. The good 
agreement of the two k2 values calculated based on the different kinetic data sources, i.e. 
Figure 1 (A) and 1 (B), substantiates that Cys-SNO disappears through the 
Cys-SH-induced bimolecular decomposition pathway (reaction 4) accompanied with 
minor Cys-SH-independent unimolecular decomposition process (reaction 2). The k1 value 
was found to be independent of the pH of the solution. 
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The values of k2 were determined in the pH range of 4.85-9.41 with the initial 
concentrations of the reactants to be [Cys-SNO] = 9 mM, [Cys-SH] = 24 mM and [buffer] = 
0.1 M, respectively.  The kinetic measurements were repeated 3-5 times for each 
condition. The k2 values determined in the solutions of different pH values at 
physiological temperature are listed in Table 1 and the pH-rate profile is shown in Fig. 2. 
It was difficult to explain such a small pH-effect, namely, that maximum value of k2 at pH 
8.15 was merely 2 folds greater than the minimum one at pH4.85, although [H+] between 
the two differed by 2 x 103 folds. 
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Discussion 
 
With respect to spontaneous unimolecular decomposition of Cys-SNO, based on k1 = 
1.46 x 10-5 s-1, the half-life of Cys-SNO in the absence of cysteine was calculated to be 
approx. 9 hr at 37°C. This value was much greater than the half-life of Cys-SNO reported 
previously, i.e. the values of approx. 1.5 hr, as calculated from the Park's second order 
rate constant if [Cys-SNO]0 = 10 mM (Park JW et al., 1988) and the values in the range of 
1-2 hr, as room temperature as reported by Arnelle and Stamler (Arnelle DR et al., 1995). 
This discrepancy would be due to the effect of trace amounts of transition metal ions, 
which were very carefully eliminated in this work as described in Experimental Section. 
Thus, the k1 value determined is the most reliable value for the uncatalyzed spontaneous 
decomposition of Cys-SNO. Such a small k1 value reveals that the spontaneous NO 
release from S-nitrosothiols may not be responsible for the biological NO transfer from 
S-nitrosothiols to soluble guanylate cyclase. Instead, the transition metal ions-catalyzed 
NO-forming reaction of S-nitrosothiols and/or direct NO transfer from nitrosothiols to the 
guanylate cyclase via bimolecular reactions of the two species may operate in the 
biological NO transfer from the S-nitrosothiols to the guanylate cyclase. The uncatalyzed 
decomposition of Cys-SNO is too slow to explain the NO-transfer from an NO-carrying 
S-nitrosothiol to cysteine residues of the target proteins via reaction 2 followed by 
reaction 1. The transnitrosation (reaction 3) may be responsible for this S-nitrosothiol 
function. 
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Next, regarding Cys-SH-induced bimolecular decomposition of Cys-SNO, 
S-nitrosothiols are thought to play the same role as NO to control vasodilation and 
antiplatelet effects, and modulation of the reactivities of hemoglobin (Jia L et al., 1996), 
prostaglandin H synthase (Hajjar DP et al., 1995), creatine kinase (Gross WL et al., 1996), 
glyceraldehyde-3-phosphate dehydrogenase (Mohr S et al., 1996) etc. by the 
transnitrosation reaction 2 to the respective cysteine residues of these proteins. 
Especially, it has been postulated that S-nitrosohemoglobin, which protects and 
transports NO in red blood cells, dispenses NO bioactivity to microvascular cells on the 
release of oxygen, physiologically coupling hemoglobin deoxygenation to vasodilation 
(Crawford JH et al., 2003; Allen BW and Piantadosi CA, 2006; Angelo M et al., 2006). 
Recently, Tejero J et al. reported that reductive nitrosylation of hemoglobin was faster at 
low NO concentrations and sensitive to allosteric modifications, indicating that it might 
be more relevant in vivo than previously recognized (Tejero J et al., 2012). If these 
S-nitrosothiol-dependent reactions contribute in biological regulations, the S-nitrosothiol 
concentrations have to be greater than the threshold in a local compartment sending the 
signal. Usual mammalian cells contain about 5 mM of the reduced form of glutathione 
(Schultz GE et al., 1979). Assuming that reactivities of intracellular S-nitrosothiols and 
thiols are the same as those of Cys-SNO and Cys-SH at least in the case of 
low-molecular-weight thiols, the pseudo-first order rate constant for the decay of an 
intracellular S-nitrosothiol to be 1.55 x 10-4 s-1 at pH7.4, at 37°C from the k2 value 
determined in this work was obtained. Under this condition, the half-life of an 
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S-nitrosothiol was calculated to be 75 min. If the rate of S-nitorosothiol formation is 
greater than 1.55 x 10-4 s-1, the intracellular concentration of S-nitorosothiol will increase.  
In my experiments, the presence of Cys-SH did not prolong the life-time of Cys-SNO 
but merely decrease it in concentration-dependent manner in contrary to the report by 
Feelish et al (Feelisch M et al., 1994). They tested the half-lives of various candidates 
containing Cys-SNO using the bioassay system comprised rabbit aortic strips, whereas I 
estimated its half-life by directly absorbance determination. The difference of 
experimental system might create this discrepancy. I would also like to mention that 
more recent kinetic studies on decomposition reaction between S-nitrosothiols and thiols 
by Hu et al. were also showed less effect on pH (Hu TM et al. 2006) along with my 
experimental results as a small pH-effect on k2.  
The apparent second order rate constants of transnitrosation reaction 3 are in the 
order of 10 M-1s-1 at pH7.4 (Barnett DJ et al., 1994; Barnett DJ et al., 1995). Therefore, in 
order that the S-nitrosation of the target protein with intracellular S-nitrosothiol 
(reaction 3) proceeds faster than the intracellular thiol dependent decomposition of the 
S-nitorosothiol (reaction 4), the concentration of the target protein should be greater than 
10-5 M. 
NO- undergoes single electron oxidation with biological oxidant (even molecular 
oxygen) yielding NO. Fukuto et al. argued that NO- was oxidized to NO (reaction 8) before 
binding to the guanylate cyclase. The guanylate cyclase requires ferrous nitrosylheme, 
[PFeII(NO)] (Craven PA et al., 1978), as a cofactor but not the ferric state. Hemin, [PFeIII], 
may accept NO- to generate [PFeII(NO)]. Then the reaction 1, 2, 4, and 8 would contribute 
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partly and explain why Cys-SH prolongs and potentiates the vasodilation effect of NO 
and Cys-SNO.  
Taken together, the present kinetic results suggest that the half-life of 
S-nitrosocysteine, which is one of endogenous S-nitrosothiols, is much longer than the 
half-life of NO in physiological environments. The fact that S-nitrosocysteine stability is 
sufficient to function as a reservoir and transporter of NO indicates S-nitrosothiols 
including S-nitrosocysteine should be able to use as an NO-generation reagent. Actually, 
some S-nitrosothiols are widely used for study on the physiological action of NO through 
to the present. Some S-nitrosothiols come into common use in life science research as 
stable NO donors, such as S-Nitroso-N-acetyl-DL-penicillamine (SNAP), 
S-nitrosoglutathione, and Cys-SNO. Especially, S-nitrosoglutathion, one of 
S-nitrosothiols, has also been used as an NO donor for treatment of patients in small 
clinical trials (Molloy J et al., 1998; Salas E et al., 1998; Rassaf T et al., 2002). 
S-nitrosoglutathione and Cys-SNO, which are derived from glutathione and cysteine 
existed widely in the body, are water-soluble and substantially play a role as 
physiologically active substance thought they are relatively unstable for practical 
purposes. SNAP is more stable than S-nitrosoglutathione and Cys-SNO but less soluble 
in water. The usage is selected from these S-nitrosothiols depending on the situation. 
Various metabolically stable substances are widely used as tool compounds in 
elucidation of reaction mechanism caused by not only short-lived molecules but also 
metabolic substrates in a state of dynamic equilibrium. For example, 
[18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) is a glucose analogue widely used to study 
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tumor metabolism and inflammatory lesion by means of positron emission tomography 
(PET). Just as glucose, FDG is actively transported into the cell mediated by a group of 
structurally related glucose transporters (GLUT). Once intracellular, both glucose and 
FDG are phosphorylated by hexokinase as the first step toward glycolysis. FDG cannot be 
further metabolized to fructose-6-phosphate by glucose-phosphate-isomerase, so FDG 
remains trapped in the cell as FDG 6-phosphate. Additionally, another example of them is 
[123I]-15-(p-iodophenyl)-3-(R,S)-methyl-pentadecanoic acid (123I-BMIPP). BMIPP is a 
methyl-branched chain fatty acid analog used as a metabolic imaging agent suitable for 
myocardial single photon emission computed tomography (SPECT). BMIPP shows high 
accumulation as well as prolonged retention in the myocardium because it is eventually, 
after -oxidation, oxidized by mitochondrial -oxidation (Yoshinaga K et al., 2007). In 
chapter 2, using two types of metabolically stable chemical probes, 
2-fluoro-2-deoxy-D-glucose (FDG) and ultrasmall superparamagnetic iron oxide (USPIO) 
particles, the difference between M1 and M2-polarized macrophages was characterized. 
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Figures and Table 
 
Figure 1.  Kinetic results for the decay of S-nitrosocysteine in the presence of cysteine at 
pH4.8 at 37°C. (A) Initial rate plot of Cys-SNO decomposition on Cys-SH concentration. 
(B) Initial rate plot of Cys-SNO decomposition on Cys-SNO concentration. 
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Figure 2.  The pH-rate constant profile for the reaction (3) at 37°C. 
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Table 1.  Second order rate constants for the reaction (6) 
 
 
  
pH k2 x 10
2
 (M
-1
 s
-1
)
4.85 1.85 ± 0.21
5.34 2.20 ± 0.13
5.92 2.88 ± 0.04
6.40 3.24 ± 0.10
7.05 2.94 ± 0.06
7.40 3.10 ± 0.03
7.60 3.43 ± 0.10
8.15 3.71 ± 0.22
8.44 3.13 ± 0.14
8.70 2.67 ± 0.14
9.00 2.29 ± 0.05
9.41 1.95 ± 0.02
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Comparison of Contrast Agents for Atherosclerosis Imaging  
Using Cultured Macrophages: Fluorodeoxyglucose versus  
Ultrasmall Superparamagnetic Iron Oxide 
 
 
 
 
 
 
 
  
32 
 
Abstract 
 
Various non-invasive imaging methods have been developed to evaluate 
atherosclerotic plaques. Among them, fluorodeoxyglucose-positron emission tomography 
(FDG-PET) and magnetic resonance imaging with ultrasmall superparamagnetic iron 
oxide particles (USPIO-MRI) have been used to quantify plaque inflammation. Both 
methods are based on the property that FDG and USPIO are efficiently taken up by 
macrophages in atherosclerotic lesions. Differently polarized macrophages have been 
reported to have different characteristics, which are involved in the pathological 
development of atherosclerosis. M1 polarized macrophages are considered as the more 
proatherogenic phenotype than M2 polarized macrophages. However, little is known 
regarding the association between macrophage polarization and FDG/USPIO 
accumulation. In this study, I investigated intracellular FDG and USPIO accumulation 
in M1 and M2 polarized macrophages. THP-1 macrophages were differentiated into M1 
and M2 polarized macrophages. Under optimal glucose conditions, the 3H-labeled FDG 
uptake in M1 and M2 polarized macrophages was investigated. Then intracellular 
USPIO uptake by M1 and M2 macrophages was investigated. As results of these 
experiments, it was found that M1 polarization results in increased intracellular 
accumulation of FDG compared to M2 polarization. To elucidate the mechanism by which 
FDG was preferentially accumulated in M1 macrophages, mRNA expressions of glucose 
transporters (GLUTs) and hexokinases (HKs), which have pivotal roles in glucose uptake, 
as well as glucose-6-phosphatase (G6Pase), which catalyzes the reverse reaction of HKs, 
were examined. In M1 macrophages, GLUT-1, GLUT-3, HK-1, and HK-2 were 
upregulated and G6Pase was downregulated. In contrast to FDG, M1 polarization 
resulted in decreased intracellular accumulation of USPIO. It was found that scavenger 
receptor A (SR-A) and CD11b, which are involved in USPIO binding/uptake, were 
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significantly downregulated by M1 polarization. In conclusion, compared to M2, 
proatherogenic M1 macrophages preferentially accumulated FDG but not USPIO, 
suggesting that FDG-PET is a useful method for the detection of proinflammatory M1 
macrophages. 
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Introduction 
 
The rupture of an atherosclerotic plaque heralds many cardiovascular complications 
such as myocardial and cerebral infarctions. Macrophage infiltration plays an important 
role in the development of vulnerable plaques. Fluorodeoxyglucose-positron emission 
tomography (18F-FDG-PET) has been reported to be a promising tool for identifying 
vulnerable atherosclerotic plaques, because their detection depends on the extent of 
macrophage infiltration into the atherosclerotic lesions (Tawakol A et al., 2006; Ogawa M 
et al., 2004; Zhang Z et al., 2006). To date, some clinical trials have been conducted to 
examine the usefulness of 18F-FDG-PET for evaluating atherosclerosis (Tawakol A et al., 
2006; Tahara N et al., 2009). Furthermore, magnetic resonance imaging with ultrasmall 
superparamagnetic iron oxide particles (USPIO-MRI) that is also efficiently taken up by 
macrophages in the atherosclerotic lesion (Trivedi RA et al., 2006; Tang TY et al., 2009) is 
used to quantify atherosclerotic plaques (Tang TY et al., 2009). Recently, macrophages 
have been considered as heterogeneous cells, which can be differently polarized in 
atherosclerotic plaques (Khallou-Laschet J et al., 2010; Feig JE et al., 2011c; Bouhlel MA 
et al., 2007). Classically activated M1 macrophages promote the destabilization of 
atherosclerotic plaques, whereas alternatively activated M2 macrophages stimulate 
reparative processes, leading to stabilization of atherosclerotic plaques (Mantovani A et 
al., 2009). Therefore, effective detection of M1 macrophages may help to predict 
cardiovascular events with greater accuracy. However, the type of macrophages that can 
be detected by FDG-PET and USPIO-MRI and the effect of macrophage polarization on 
FDG and USPIO accumulation are still unclear. 
I report here the relationship between the macrophage polarization and imaging 
probe uptake to the cells. I first investigated the association between macrophage 
polarization and FDG/USPIO accumulation using human THP-1 macrophages. Then, to 
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elucidate the molecular mechanism of FDG/USPIO accumulation in polarized 
macrophages, I analyzed the expression of genes responsible for FDG uptake and 
metabolism and USPIO uptake and iron export. 
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Materials and Methods 
 
Cell Culture and Chemicals 
Human THP-1 cells were obtained from Dainippon Sumitomo Pharma (Osaka, 
Japan). Cell culture media were purchased from Life Technologies (California, USA). 
Fetal bovine serum (FBS) was obtained from Thermo Fisher Scientific (Massachusetts, 
USA). Phorbol 12-myristate 13-acetate (PMA) was obtained from WAKO pure chemicals 
(Osaka, Japan). Lipopolysaccharides (LPS) from Escherichia coli O111: B4 was obtained 
from Sigma-Aldrich (Saint Louis, USA). Recombinant human interferon- (IFN), human 
interleukin (IL)-4, and human IL-13 were obtained from R&D Systems (Minneapolis, 
USA). [5,6-3H]-2-Fluoro-2-deoxy-D-glucose (3H-FDG) was obtained from American 
Radiolabeled Chemicals (Saint Louis, USA). USPIO coated with alkali-treated dextran 
(average particle size, 28 nm) was custom synthesized by Meito Sangyo (Nagoya, Japan). 
 
Differentiation of THP-1 Cells into Macrophages and Polarization 
THP-1 cells were cultured in RPMI1640 supplemented with 10% heat-inactivated 
FBS, 100 U/mL penicillin and 100 g/mL streptomycin. THP-1 cells (seeded at 2 × 105 
cells/cm2) were differentiated into macrophages using 320 nM PMA and polarized 
according to the method of Tjiu et al. with some modifications (Tjiu JW et al., 2009). For 
M1 polarization, cells were treated with PMA for 6 h, and then cultured with PMA plus 
LPS (10 ng/mL) and IFN (20 ng/mL) for another 42 h. For M2 polarization, cells were 
treated with PMA for 6 h, and then cultured with PMA plus IL-4 (20 ng/mL) and IL-13 (20 
ng/mL) for another 42 h. I also developed control macrophages, which received no stimuli, 
that were differentiated from THP-1 cells by incubation with PMA for 48 h. To evaluate 
the appropriate induction of polarization, I measured an M1 marker gene, inducible nitric 
oxide synthase (iNOS), and an M2 marker gene, mannose receptor C type 1 (MRC1). 
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3H-FDG Study 
Polarized macrophages were rinsed and then precultured in RPMI1640 containing 1 
mM glucose at 37°C for 1 h. After the media were replaced with fresh media containing 1 
mM glucose and 3H-FDG (3.7 kBq/well), cells were cultured for another 3 h. Cells were 
washed twice with pre-chilled saline containing 25 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM CaCl2, and 1 mM 
MgCl2, and were dissolved with 0.1% sodium dodecyl sulfate/0.1 M NaOH aqueous 
solution. The radioactivities of culture media and cell lysates were measured using a 
liquid scintillation counter (Accu FLEX LSC 7400; Hitachi Aloka Medical, Ltd., Tokyo, 
Japan). Cellular protein concentration was measured using the DC Protein Assay Kit 
(Bio-Rad, California, USA). 3H-FDG accumulation was expressed as radioactivities in cell 
lysate per milligram of cell protein. 
 
USPIO Study 
Macrophages were incubated with USPIO (400 g Fe/mL) for the last 16 h of the 
2-day treatment with polarizing stimulus at 37°C in 5% CO2. The cells were washed twice 
with pre-chilled saline containing 25 mM HEPES, 1 mM CaCl2, and 1 mM MgCl2 and 
were dissolved with 0.5% Triton X-100 aqueous solution. Iron contents of cell lysates were 
measured using the Iron Assay Kit (BioChain, California, USA). Cellular protein 
concentration was measured using the DC Protein Assay Kit. The USPIO accumulation 
was expressed as cellular iron content per milligram of cell protein. 
 
Gene Expression Analysis of Polarized Macrophages 
Cellular total RNA was extracted using the RNeasy mini kit (QIAGEN, Hilden, 
Germany) and converted into cDNA using the High Capacity cDNA Reverse Transcription 
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Kit (Life Technologies, California, USA). Gene expression was analyzed using the 
7900HT Fast Real-Time PCR System (Life Technologies, California, USA) with the 
TaqMan® Universal Master Mix II (Life Technologies, California, USA) and primer-probe 
sets of TaqMan Gene Expression Assays (Life Technologies, California, USA) for the 
following genes: iNOS (Hs00167248_m1), MRC1 (Hs00267207_m1), scavenger receptor A 
(SR-A; Hs00234012_m1), glucose transporter (GLUT)-1 (Hs00892681_m1), GLUT-3 
(Hs00359840_m1), hexokinase1 (HK1; Hs00175976_m1), hexokinase2 (HK2; 
Hs00606086_m1), glucose-6-phosphatase (G6Pase; Hs00292720_m1), CD11b 
(Hs00355885_m1), CD36 (Hs00354519_m1), ferroportin 1 (Fpn1; Hs00205888_m1), and 
ferritin light chain (FTL; Hs00830226_gH). -Actin (Hs99999903_m1) was used as an 
endogenous control gene. Relative mRNA expression was calculated using the CT 
method.  
 
Animals 
All animal experimental procedures were performed according to the guidelines of the 
Takeda Experimental Animal Care and Use Committee. Male apolipoprotein E knockout mice 
(ApoE−/−, C57BL/6J) fed high-fat diet (D12451, Research Diet, New Brunswick, USA) for 25 
weeks starting at the age of 10 weeks.  
 
Autoradiography and Oil Red O Staining 
ApoE knockout mice fed high-fat diet were anaesthetized with sodium 
thiobutabarbital (120 mg/kg i.p.) and then intravenously injected with 14C-FDG (280 
kBq/mouse). The animals were kept without food O/N before injections of the radiotracers 
until sacrifice. Three hours after 14C-FDG injections, mice were sacrificed under 
anesthesia and whole aorta were dissected. Excised aortas were longitudinally opened 
and exposed to a BAS-III imaging plate (FujiFilm, Tokyo, Japan) at -30°C for 2 days. The 
signals were detected by autoradiography using a FLA-7000 (FujiFilm). Following 
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autoradiography, the whole aortas were fixed with 10% formalin and then stained with oil 
red O.  
 
Gene Expression Analysis of Atherosclerotic Plaques  
ApoE knockout mice fed high-fat diet were sacrificed under anesthesia with sodium 
pentobarbital (55 mg/kg, i.p.) and the whole aortas were dissected after saline perfusion. 
The plaques in the arch and abdominal aorta were picked away and subjected to total 
RNA extraction. The mRNA expression was analyzed by real-time PCR method with the 
primer-probe sets of TaqMan Gene Expression Assays for the following genes: iNOS 
(Mm01309902_m1), IL-1 (Mm00434228_m1), CCR7 (Mm01301785_m1), MRC1 
(Mm01329362_m1), CD68 (Mm03047343_m1),-actin (Mm00607939_s1). -actin was 
used as the internal standard gene.  The relative expression level was calculated by 
CT methods. 
 
Statistics 
Data are presented as mean ± SD. Statistical analyses were performed using SAS 
software (version 8.2; SAS Institute, Inc., Cary, NC). Either Tukey's parametric multiple 
comparison test or Steel–Dwass's nonparametric multiple comparison test (Bartlett's 
test; P < 0.05) was used for comparisons among the three different macrophage types, 
namely, M1, M2, and control macrophages. P values of < 0.05 were considered 
statistically significant. 
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Results 
 
Macrophage Polarization 
Macrophages treated with IFN/LPS showed significant upregulation of iNOS (Fig. 
3A) (P < 0.05), whereas those treated with IL-4/IL-13 showed significant upregulation of 
MRC1 (Fig. 3B) (P < 0.05). The M1 marker genes CCR7 and IL-1 were also significantly 
upregulated in macrophages treated with IFN/LPS, and the M2 marker gene IL-1ra was 
significantly upregulated in macrophages treated with IL-4/IL-13 (data not shown). 
Hence, I used these macrophages as for M1 polarization and M2 polarization for the 
following experiments. 
 
3H-FDG Accumulation in M1 and M2 Macrophages 
To study accumulation of FDG in macrophages, I first optimized the glucose 
concentration in the medium, since FDG-PET signals decrease if blood glucose levels 
exceed 200 mg/dL. In a preliminary study using a medium containing a high glucose 
concentration of 200 mg/dL, FDG accumulation in macrophages was markedly reduced 
(data not shown). In a low glucose medium of 1.8 mg/dL (approx. 0.1 mM), I observed that 
cells were damaged (data not shown). Therefore, I added glucose at 1 mM to the medium, 
so as to be sufficient to detect FDG accumulation without damaging the cells. M1 
macrophages showed a 2.6-fold increased uptake of 3H-FDG compared to M2 
macrophages (Fig. 4) (P < 0.01). 
 
Expression of Glucose Metabolism-Related Genes in Macrophages 
I measured the mRNA expression of glucose metabolism-related genes to elucidate 
the mechanism by which FDG was preferentially taken up by M1 macrophages. I found 
that GLUT-1 and GLUT-3, which are major isoforms of a glucose transporter in 
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macrophages (Fu Y et al., 2004; Ahmed N et al., 1997), were significantly upregulated in 
M1 macrophages compared to M2 macrophages (Fig. 5) (P < 0.01 and P < 0.01, 
respectively). HK1 and HK2, which catalyze the intracellular phosphorylation of glucose 
into glucose-6-phosphate, were also significantly upregulated in M1 macrophages 
compared to M2 macrophages (Fig. 5) (P < 0.01 and P < 0.01, respectively). However, the 
expression of G6Pase, which is an enzyme that catalyzes the reverse reaction of 
hexokinases, was significantly downregulated in M1 macrophages compared to M2 
macrophages (Fig. 5) (P < 0.01). These results suggest that the increase of FDG 
accumulation in M1 macrophages was caused by the upregulation of GLUT and HK genes, 
as well as the downregulation of G6Pase gene. 
 
USPIO Accumulation in M1 and M2 Macrophages  
Previous USPIO accumulation studies have used macrophages treated with USPIO 
in concentrations ranging from 50 to 500 g Fe/mL and in time periods lasting 1 to 72 h 
(Lunov O et al., 2011; Müller K et al., 2008; Yancy AD et al., 2005; Raynal I et al., 2004). 
On the basis of our preliminary study findings, macrophages were incubated with USPIO 
(400 g Fe/mL) for the last 16 h of the 2-day treatment with polarizing stimulus at 37°C 
in 5% CO2. USPIO accumulation in the cells increased linearly with both USPIO 
concentration and incubation time. In contrast to FDG, USPIO accumulation in M2 
macrophages was 1.4-fold higher than that in M1 macrophages (Fig. 6) (P < 0.01). 
 
Expression of USPIO Uptake- and Iron Export-Related Genes in Macrophages 
To elucidate the mechanism by which USPIO was preferentially taken up by M2 
macrophages compared to M1 macrophages, I measured the mRNA expression of SR-A 
and CD11b (Lunov O et al., 2011; von Zur Muhlen C et al., 2007). Both SR-A and CD11b 
were significantly upregulated in M2 macrophages compared to M1 macrophages (Fig. 7) 
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(P < 0.01 and P < 0.01, respectively). Considering that other scavenger receptors may 
contribute to the uptake of USPIO, I measured the expression of CD36, another major 
scavenger receptor. As shown in Fig. 7, CD36 was also upregulated in M2 macrophages. 
The expression of Fpn1, the major iron exporter in mammalian cells (Donovan A et al., 
2005), was also significantly upregulated in M2 macrophages compared to M1 
macrophages (Fig. 7) (P < 0.01). There was no significant difference in the expression of 
FTL, which is responsible for intracellular iron storage (Torti FM et al., 2002), between 
M1 macrophages and M2 macrophages (Fig. 7).  
 
14C-FDG Accumulation in Murine Atherosclerotic Plaques 
Next, I qualitatively investigated 14C-FDG accumulation ex vivo in atherosclerotic 
plaques of ApoE knockout mice fed high fat diet as murine model of atherosclerosis. Oil 
red O staining revealed that atherosclerotic plaques were rich in both arch and 
abdominal aorta in this atherosclerosis model. Notwithstanding, signals of 14C-FDG 
accumulation were observed stronger in the abdominal plaques compared to plaques in 
the aortic arch in en face autoradiography of the whole aorta of 14C-FDG injected ApoE 
KO mice (Fig. 8). 
 
Expression of Polarized Macrophage Marker in Murine Atherosclerotic Plaques 
To investigate the relationship between 14C-FDG accumulation and macrophage 
polarization in atherosclerotic plaques in this mouse model, the expression level of 
marker genes of macrophage polarization was subsequently measured. The expression of 
M1 marker genes, such as iNOS, IL-1, CCR7, was upregulated in the abdominal plaques 
where more 14C-FDG was accumulated than the aortic arch ones (Fig. 9). Conversely, the 
expression of M2 marker gene MRC1 was significantly upregulated in the aortic arch 
plaques (Fig. 9) (P < 0.05). The expression of macrophage marker gene CD68 was not 
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different significantly between the aortic arch plaques and the abdominal one (Fig. 9).  
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Discussion 
 
FDG-PET and USPIO-MRI have been clinically used to quantify atherosclerotic 
plaques, because both FDG and USPIO are efficiently taken up by macrophages in 
atherosclerotic lesions. Recently, macrophages in varying polarized states have been 
reported to have different characteristics that are involved in the pathological 
development of atherosclerosis (Khallou-Laschet J et al., 2010; Mantovani A et al., 
2009). In this study, I compared the ability of differently polarized macrophages to take 
up FDG and USPIO using human THP-1 macrophages. I showed that FDG was taken up 
preferentially by M1 macrophages, whereas USPIO was taken up by M2 macrophages.  
The preferential uptake of FDG by M1 macrophages led to the hypothesis that M1 
and M2 differed in the expression of the glucose uptake-related molecules because FDG is 
taken up by cells in a manner analogous to glucose. I observed that the mRNA expression 
of GLUT-1 and GLUT-3 was upregulated in M1 macrophages. Kim et al. also reported 
that the mRNA expression of GLUT-1 was upregulated and intracellular FDG 
accumulation increased in mouse RAW264.7 macrophages stimulated by LPS (Kim C et 
al., 2009). In addition, I showed that the mRNA expression of HK1 and HK2, which are 
major hexokinase isoforms, was upregulated, whereas the mRNA expression of G6Pase 
was downregulated in M1 macrophages. FDG is taken up into cells via glucose 
transporters and then phosphorylated by hexokinases to FDG-6-phosphate (FDG6P) in a 
mechanism similar to glucose. FDG6P is retained inside the cell, such that it can neither 
follow the process of glycolysis nor easily pass through the plasma membrane. If G6Pase, 
the catalyst of the reverse reaction of hexokinase, converts FDG6P into FDG, FDG can 
theoretically diffuse out of cells via glucose transporters. The present study suggests that 
the regulation of gene expression of key molecules involved in glucose uptake contributed 
to the increase in intracellular FDG accumulation in M1 macrophages. In particular, the 
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increased intracellular FDG uptake via glucose transporters, the phosphorylation of FDG 
by hexokinases, and the decrease in dephosphorylation of FDG6P by G6Pase contributed 
to the increase of FDG uptake in M1 macrophages. On the other hand, inconsistent with 
our observation, Folco et al. reported that inflammatory stimulation did not increase the 
glucose uptake in human primary monocytes (Folco EJ et al., 2011). They used IFN or a 
combination of IFN, TNF and IL-1 as inflammatory stimulation, whereas I adopted a 
classical M1 stimulation for characterizing typical phenotypes of M1 macrophages. I need 
to consider a more relevant stimulation to atherosclerosis in the future experiments. 
Small iron oxide particles (SPIO) and USPIO have been used clinically as 
superparamagnetic MRI contrast agents. These iron oxide particles are efficiently taken 
up by macrophages. A range of molecules is considered to be involved in SPIO/USPIO 
uptake and iron export. Lunov et al. identified the clathrin-mediated SR-A dependent 
endocytosis as a major pathway of USPIO uptake in peripheral blood monocyte-derived 
macrophages (Lunov O et al., 2011). Muhlen et al. showed that USPIO uptake was 
inhibited by treatment with anti-CD11b antibody in PMA-stimulated human peripheral 
blood monocytes (von Zur Muhlen C et al., 2007). In the present study, I determined that 
both SR-A and CD11b were significantly upregulated in M2 macrophages, which might 
contribute to the increase in USPIO uptake by M2 macrophages (Fig 7). Gu et al. reported 
that internalized USPIO in mouse macrophages was degraded in lysosomes and free iron 
was released into intracellular iron pools (Gu J et al., 2011). Fpn1 is known to have an 
important role in the export of iron from cells (Donovan A et al., 2005). I observed that 
Fpn1 was also upregulated in M2 macrophages compared to M1 macrophages (Fig. 7), 
consistent with the previous report (Recalcati S et al., 2010). In the present study, I 
observed statistically significant increase of USPIO uptake in M2 macrophages compared 
to M1 macrophages, but the difference was relatively small, in spite of the marked 
induction of genes related to uptake of USPIO. The upregulation of Fpn1 could cause the 
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reduction of the cellular iron levels, which might attenuate the accumulation of USPIO in 
M2 macrophages. Taken together, accumulation of cellular USPIO was higher in M2 
macrophages than in M1 macrophages, most likely as a result of the balance of 
transcriptional regulation of genes related to uptake and export of USPIO. In the present 
study, there were no difference in USPIO accumulation between M2 macrophages and 
control ones (Fig. 6), suggesting the difficulty of visualizing only M2 macrophages in 
distinction from non-polarized macrophage by USPIO. Recently, it has been reported that 
the status of macrophages polarization in atherosclerotic plaques was dramatically 
changed in the progression and regression process of atherosclerosis using experimental 
murine model (Feig JE et al., 2011c; Feig JE et al., 2011p). In addition, a substantial 
number of macrophages was polarized in those lesions. Therefore, USPIO should be able 
to light-up the mainly M2-lesion, although I need to pay attention to the false-positive 
results. In contrast to our findings, Rogers et al. reported that not only Th2 cytokine IL-4 
but also Th1 cytokine IFN increased SPIO uptake in mouse J774A.1 macrophages 
(Rogers WJ et al., 2005). However, differing experimental conditions including cell type 
and polarization methods might explain these discrepancies. Rogers et al. used IFN and 
IL-4 alone as Th1 and Th2 cytokines, respectively, whereas I used IFN in addition to 
LPS and IL-4 plus IL-13 as M1-polarizing and M2-polarizing stimuli, respectively. In this 
study, I investigated the USPIO uptake with a 16 h incubation to obtain the reasonably 
enough amount of intracellular USPIO for quantitative analysis, while the incubation 
time was 3 h for FDG. The exposure time might affect the uptake of FDG and USPIO in 
M1 and M2 polarized macrophages. Cell viability also should be another important factor 
to evaluate the cellar uptake. In this study, at least, the cell damage was not observed 
morphologically. Further investigation about exposure time and cell viability should be 
needed for the precise analysis. 
The ultimate purpose of atherosclerosis imaging, and the detection of vulnerable 
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rupture-prone plaques in particular, is the accurate prediction of cardiovascular events. 
Recently, studies have suggested that the quality rather than quantity of macrophages is 
critical in the evolution of vulnerable plaques (Hartung D et al., 2007; Matter CM et al., 
2006; Jarrett BR et al., 2010). M1 macrophages play a key role in the development of 
atherosclerosis, which is mediated by production of proinflammatory cytokines and/or 
reactive nitrogen oxides, whereas M2 macrophages have antiatherogenic properties 
mediated by the production of anti-inflammatory cytokines and the suppression of 
proinflammatory signaling (Gordon S et al., 2005; Wolfs IM et al., 2011). However, the 
contribution of these differently polarized macrophages to vulnerable plaque formation, 
potentially resulting in plaque rupture has not yet been fully understood. For example, 
Mauriello et al. recently reported that M2 but not M1 macrophages were present in the 
fibrous cap near the rupture site in the human carotid artery, suggesting that M2 
macrophages might also modulate the process of plaque rupture (Mauriello A, et al., 
2011). Although further investigations regarding the roles of M1 and M2 macrophages in 
atherosclerotic lesions are needed, it is clear that macrophage polarization affects plaque 
diagnosis and prognosis. Ex vivo study, stronger signals were observed in abdominal 
plaques compared to plaques in the aortic arch in en face autoradiography of the whole 
aorta of 14C-FDG injected ApoE KO mice (Fig. 8). The M1 markers iNOS, IL-1, CCR7 
were upregulated in the abdominal plaques, while the M2 marker MRC1 was 
upregulated in the aortic arch plaques (Fig. 9). These results suggest that 18F-FDG-PET 
should dominantly visualize the M1 macrophage infiltrated area though there is the 
limitation that number of macrophages in each atherosclerotic plaque is not able to be 
normalized by molecular biological technique. With respect to this consideration, an 
additional investigation on quantification of macrophage content in atherosclerotic 
plaques by an immunohistochemical method will lead to a more precise result. Some 
reports have suggested that 18F-FDG-PET may be useful to monitor the therapeutic 
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effects of drugs (Fayad ZA et al., 2011; Tahara N et al., 2006; Ogawa M et al., 2006), and 
some of the drugs are reported to affect the polarization of macrophages (Bouhlel MA et 
al., 2007; Feig JE et al., 2011c; Aki K et al., 2010; Fujita E et al, 2010). Because therapies 
which reduce M1 macrophages are garnering more attention, it becomes increasingly 
important to select appropriate imaging methods that accurately detect plaque 
development.  
In conclusion, the present study provides in vitro evidence that 18F-FDG PET 
preferentially detects proinflammatory M1 macrophages, whereas USPIO MR imaging 
preferentially detects anti-inflammatory M2 macrophages. Although further in vivo 
investigations are needed, 18F-FDG PET imaging should be useful in the detection of 
proinflammatory M1 macrophages. 
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Figures 
 
Figure 3.  Gene expression of M1 and M2 markers in human THP-1 macrophages 
treated with each polarizing factor: (A) iNOS as M1 marker, (B) MRC1 as M2 marker. 
Data are presented as mean ± SD (N = 6). *P < 0.05 compared between M1 and M2; #P < 
0.05 compared to No stimuli by Steel-Dwass test. 
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Figure 4.  Intracellular [3H]FDG accumulation in human THP-1 macrophages. Data are 
presented as mean ± SD (N = 6). **P < 0.01 compared between M1 and M2; ##P < 0.01 
compared to No stimuli by Tukey test. 
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Figure 5.  Expression of glucose metabolism-related genes in human THP-1 
macrophages: (A) GLUT-1, (B) GLUT-3, (C) HK1, (D) HK2, (E) G6Pase. Data are 
presented as mean ± SD (N = 6). **P < 0.01 compared between M1 and M2; ##P < 0.01 
compared to No stimuli by Tukey test. 
 
 
  
0.0 
0.5 
1.0 
1.5 
2.0 
No stimuli M1 M2
R
e
la
ti
v
e
 G
L
U
T
-1
 m
R
N
A
**
##
##
0.0 
0.5 
1.0 
1.5 
2.0 
No stimuli M1 M2
R
e
la
ti
v
e
 H
K
2
 m
R
N
A
**
##
##
0.0 
0.5 
1.0 
1.5 
No stimuli M1 M2
R
e
la
ti
v
e
 G
6
P
a
s
e
 m
R
N
A
**
##
##
0.0 
1.0 
2.0 
3.0 
4.0 
No stimuli M1 M2
R
e
la
ti
v
e
 G
L
U
T
-3
 m
R
N
A
**
##
##
0.0 
1.0 
2.0 
3.0 
No stimuli M1 M2
R
e
la
ti
v
e
 H
K
1
 m
R
N
A **
##
##
A B
C D E
52 
 
Figure 6.  Intracellular USPIO accumulation in human THP-1 macrophages. Data are 
presented as mean ± SD (N = 6). **P < 0.01 compared between M1 and M2; ##P < 0.01 
compared to No stimuli by Tukey test. 
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Figure 7.  Expression of USPIO uptake- and iron export-related genes in human THP-1 
macrophages: (A) SR-A, (B) CD11b, (C) CD36, (D) Fpn1, (E) FTL. Data are presented as 
mean ± SD (N = 6). *P < 0.05, **P < 0.01 compared between M1 and M2; #P < 0.05, ##P < 
0.01 compared to No stimuli by Tukey test of Steel-Dwass test. 
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Figure 8.  Autoradiography (A) and corresponding oil red O staining (B) in mouse aortas 
after 14C-FDG injections. The aortas with the same numbers indicated in the figure were 
obtained from the same animals. 
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Figure 9.  Gene expression of M1 (iNOS, IL-1, CCR7) , M2 (MRC1) and macrophage 
(CD68) markers in the aortic arch (white bar) and abdominal (black bar) plaques from 
ApoE knockout mice. Data are presented as mean ± SD (N = 6). *P < 0.05 by Student t 
test. 
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General Discussion 
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In this thesis, I investigated the usefulness of metabolically stable compounds, such 
as S-nitrosocysteine, FDG, and USPIO, as tools for various biological approaches. In 
Chapter 1, the decomposition kinetics of S-nitrosocysteine, one of endogenous 
S-nitrosothiols, were investigated in order to understand its usefulness as a sustainable 
NO donor. I discussed the physiological role and usefulness of S-nitrosocysteine and the 
future perspective to its clinical translation, led by my study. In Chapter 2, 
M1/M2-polarized macrophages were characterized using two types of chemical probes, 
FDG and USPIO, which were metabolized through different pathways. Biological readout 
of the imaging using FDG and USPIO in atherosclerosis was discussed based on kinetic 
research of these compounds in the different type of macrophages. I also discussed the 
results from the point of view of translational research. 
In chapter 1, in order to investigate whether S-nitrosothiols could work as an NO 
donor in a body, its decomposition rate was evaluated in the presence of cysteine for 
mimicking a physiological condition. For this study, I used S-nitrosocysteine which is 
structurally the simplest S-nitrosothiol presented in cells and blood. S-nitrosocysteine 
was physiologically produced via S-nitrosation of cysteine by nitrous acid that is produced 
from NO in the presence of oxygen (reaction 1), or via transnitrosation reaction between 
an S-nitrosothiol and cysteine (reaction 3). The present study indicated that a half-life of 
S-nitrosocysteine was approx. 75 min, much longer half-life than NO, suggesting that 
S-nitrosocysteine could function as a NO reservoir in physiological conditions. It has been 
reported that high-molecular-weight S-nitrosothiols such as S-nitrosoalbumin and 
S-nitrosohemoglobin showed a more sustainable property, compared to 
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low-molecular-weight S-nitrosothiols, such as S-nitrosocysteine and S-nitrosoglutathione. 
For example, the half-life of S-nitrosoalbumin in human plasma in vitro was 5.5 hours 
determined by GC-MS (Tsikas D et al., 1999). Because NO itself is a labile free radical 
with the biological half-life of several seconds, Cys-34 residue of serum albumin is 
nitrosylated to form long lived S-nitrosoalbumin, which may act as a reservoir of NO in 
blood (Simon DI et al., 1993; Shcarftein JS et al., 1994). In physiological conditions, NO is 
supposed to be stored as stable high-molecular-weight S-nitrosothiols by a rapid 
transnitrosation reaction, whose nitroso group is then transferred into low–
molecular-weight S-nitrosothiols, particularly S-nitrosocysteine. S-nitrosocysteine 
crosses the plasma membrane into intracellular targets via the L-type amino acid 
transporters (Li S et al., 2005), and then is degraded to release NO both enzymatically 
and non-enzymatically and functions as an intracellular NO donor. On the other hand, 
NO is oxidized to nitrous acid in the presence of oxygen, and transported in blood as a 
form of nitrite ion. It has been reported that protonation of nitrite ion produces 
nitrosonium ion (NO+), which reacts with thiols in blood, and is converted into 
S-nitrosothiols (Grossi L et al., 2002). S-nitrosothiols also have a physiological important 
role in this recycling pathway of NO. It is indicated that S-nitrosothiols including 
S-nitrosocysteine can become a tool compound to elucidate various physiological function 
of NO, because they are produced endogenously and have a sufficient stability to function 
in vivo. Actually, S-nitrosothiols are used widely for the research of NO especially in 
cardiovascular system. Previous reports (Hogg N, 2000; Richardson G et al., 2002) and 
the present result indicate that the some S-nitrosothiols are useful as sustainable 
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NO-generating tools for the NO research, and overcome the problem related to extreme, 
highly unstable property of NO molecule. Moreover, S-nitrosoglutathion, one of 
S-nitrosothiols, has also been used as an NO donor for treatment of patients in small 
clinical trials (Molloy J et al., 1998; Salas E et al., 1998; Rassaf T et al., 2002). However, 
S-nitrosothiols have not yet been launched in the market, because their decomposition 
rate is unpredictable because various factors, such as trace amounts of copper ions, 
enzymatic degradation, and transnitrosation with other thiols, affects their 
decomposition (Richardson G et al, 2002). Although the clinical use of S-nitrosothiols is 
currently challenging, other approaches to increase NO by eNOS activation are clinically 
available at present. There are some launched drugs which increase eNOS activity. For 
example, 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors as 
anti-hyperlipidemic drugs, angiotensin-converting enzyme (ACE) inhibitors as 
anti-hypertensive drugs, and prostacyclin analogues as drugs for pulmonary 
hypertension and peripheral arterial disease increase NO production based on 
upregulation of eNOS at mRNA level. These drugs improve vascular endothelial 
functions due to vasodilatory effect and inhibitory effect of platelet aggregation via NO 
elevation. However, other approaches to increase NO are still desired. Further researches 
on the mechanism of the decomposition of S-nitrosothiols are required for their clinical 
usage as NO donors. The present research might help to understand this mechanism. 
In chapter 2, I studied the difference on the characteristics of M1/M2-polarized 
macrophages by use of two types of contrast agent, FDG and USPIO. FDG, which is an 
analogue of glucose, is taken up by cells via GLUTs and phosphorylated to 
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FDG-6-phosphate by HKs to the same extent as glucose. However, FDG-6-phosphate is 
unable to be metabolized further in the glycolytic pathway and remains within the cells 
differently from glucose-6-phosphate. Therefore, glucose uptake can be stably monitored 
using this stable contrast agent (Sheikine Y and Akram K, 2010). Conversely, USPIO is 
iron oxide nanoparticles coated with dextran with a mean diameter of approx. 30 nm, 
similar to that of low density lipoprotein (LDL) (15 to 25 nm). Macrophages take up 
proatherogenic lipoproteins as oxidized LDL through scavenger receptors and are converted 
into foam cells. It has reported that USPIO particles are taken up by macrophages via the 
scavenger receptor-mediated endocytosis (von Zur Muhlen C et al., 2007; Lunov O et al., 
2011), and metabolized via the lysosomal pathway (Schulze E et al., 1995). In vascular 
vessels, the inflammatory response induced by M1 macrophages within the 
atherosclerotic plaque stimulates macrophages both to undergo apoptosis, which 
contributes to necrotic core formation, and to secrete matrix metalloproteinases (MMPs), 
which degrade the fibrous cap, and then promotes plaque instability (Tiwari RL et al., 
2008; Moore KJ et al., 2011). The present study clearly demonstrated that inflammatory 
M1 macrophages preferentially accumulated FDG than USPIO, due to upregulation of 
both glucose uptake and glucose phosphorylation in M1 macrophages. It is important to 
translate in vitro observation into in vivo situation, especially clinical one. In the ex vivo 
study of mouse model of atherosclerosis, signals of 14C-FDG accumulation were observed 
stronger in the abdominal plaques compared to plaques in the aortic arch in en face 
autoradiography of the whole aorta of 14C-FDG injected ApoE KO mice. The expression of 
M1 marker genes, such as iNOS, IL-1, CCR7, was upregulated in the abdominal plaques 
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where more 14C-FDG was accumulated than the aortic arch ones, suggesting that FDG 
accumulation was enhanced in an atherosclerotic plaque which was increased the ratio of 
M1-polarized inflammatory macrophages. I selected high fat diet-fed ApoE KO mice as a 
mouse model of atherosclerosis because they were known to spontaneously develop 
unstable atherosclerotic plaques whose disruption caused cardiovascular events (Jackson 
CL et al., 2007; Matoba T et al., 2013). However, some researchers pointed out the species 
difference between mice and humans regarding the complexity of their atherosclerotic 
lesion (Schwartz SM et al., 2007). For extrapolating the present study into clinical 
atherosclerosis, further investigations are needed about histopathological analysis of the 
mouse model using in this study, including quantitative determination of infiltrating 
macrophages in atherosclerotic lesion. However, the present results are consistent with 
clinical observations, because it has been reported that the pharmaceutical intervention 
of anti-atherosclerotic drugs, such as pioglitazone, polarized macrophages in human 
atherosclerotic lesion to M2 (Bouhlel MA et al., 2007), and decreased FDG accumulation 
in atherosclerotic lesion by FDG-PET study via attenuation of atherosclerotic plaque 
inflammation (Mizoguchi M et al., 2011). The selection of an appropriate probe to detect 
inflammatory M1 macrophages leads to the improvement of a predictive probability for 
cardiovascular events, because inflammatory macrophages contribute to promote the 
destabilization of atherosclerotic plaques. The present study strongly suggests that FDG 
can be more useful than USPIO as an imaging probe that detects the inflammatory M1 
macrophages. 
The metabolically stable compounds in the body are useful for not only investigating 
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various life phenomena, but also applying to our life such as clinical diagnosis and 
therapy. In addition, it is essential for life sciences to explore new metabolically stable 
chemical probes designed by modification of endogenous molecules. 
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